Tisdag 12 November | 00:31:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-04-25 - Årsstämma
2025-02-26 08:30 Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av analytiska program. Produktportföljen är bred och inkluderar exempelvis program för intern uppföljning, process- samt systemhantering. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster inom arbetsområdet. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Magle Chemoswed har sitt huvudkontor i Malmö.
2024-10-02 09:00:00

In an ambitious move to transform wound care, Magle Chemoswed and I2Pure have unveiled a joint venture, marrying I2Pure's groundbreaking molecular iodine technology with Magle Chemoswed's innovative starch microspheres. This collaboration is poised to address critical patient needs and significantly enhance treatment outcomes in wound care.

I2Pure, known for its dedication to infection prevention through non-toxic molecular iodine technology, joins forces with Magle Chemoswed, a leader in biodegradable starch microsphere technology (DSM). Together, they are developing a novel product aimed at preventing infection and facilitating more effective wound treatment. Early formulation and efficacy testing have delivered very promising results, showcasing the potential of this partnership to make a meaningful impact on wound care.

Jeff Jochims, CEO of I2Pure, commented on the venture, "This collaboration brings together significant expertise and innovative technology to tackle challenges in wound care. Our goal is to provide better products to patients and healthcare providers across the globe."

Camilla Gummesson, Director of R&D at Magle Chemoswed, also expressed her optimism about the project's future, stating, "By integrating I2Pure's iodine technology with our DSM, we're crafting a wound care solution that not only meets but exceeds current patient needs. The encouraging results from our initial tests are a testament to the potential of this partnership."

Accelerated Development and Pre-Clinical Testing
Following the promising outcomes of the first formulation and efficacy tests, the venture is expediting the prototype into pre-clinical testing. This swift advancement underscores the commitment of both companies to fast-track the delivery of this innovative solution to the market, aiming to significantly improve care and outcomes in wound management. This joint venture marks a significant milestone in the ongoing effort to enhance healthcare interventions, particularly in wound care, by making them safer and more effective. The collaboration between Magle Chemoswed and I2Pure is a testament to their shared vision of elevating healthcare standards and offering groundbreaking solutions to patients and healthcare practitioners.

About I2Pure
I2Pure is a healthcare technology company dedicated to advancing the world of health and biosafety by preventing infections and disease through its patented, non-toxic molecular iodine platform. I2Pure’s mission is to prevent pathogenic threats to the world. Our technology can be used across virtually every facet of surgical and therapeutic interaction with human or animal tissue to prevent infection. The platform technology can be delivered via solutions, polymers and coatings and can be extended into medical devices, antisepsis, cosmetics, water safety, food safety and preservation, aquaculture and more.